澳洋健康(002172) - 2020 Q3 - 季度财报
AYJKAYJK(SZ:002172)2020-10-23 16:00

Financial Performance - Operating revenue for the reporting period was ¥784,459,238.10, representing an increase of 11.65% year-on-year[7]. - Net profit attributable to shareholders was a loss of ¥96,048,034.59, a decrease of 7.46% compared to the same period last year[7]. - The net cash flow from operating activities was a negative ¥108,579,382.38, a decline of 348.62% compared to the same period last year[7]. - Basic earnings per share were -¥0.12, an increase of 7.69% year-on-year[7]. - The weighted average return on net assets was -7.65%, a decrease of 1.94% compared to the same period last year[7]. - Net profit increased by 50.47% year-on-year, mainly due to an increase in demolition compensation income[15]. - Net loss for Q3 2020 was CNY 98,570,199.78, compared to a net loss of CNY 142,881,337.89 in the same period last year[39]. - Net profit for the period was a loss of CNY 213,990,094.33, compared to a loss of CNY 432,053,822.28 in the same period last year, indicating an improvement[46]. - The total comprehensive income for the period was a loss of CNY 213,990,094.33, compared to a loss of CNY 432,053,822.28 in the previous period[47]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,396,981,853.21, an increase of 0.78% compared to the end of the previous year[7]. - The company's total liabilities rose to ¥5,171,436,930.66 from ¥4,905,453,936.96, reflecting an increase of approximately 5.4%[31]. - The total current liabilities decreased to ¥4,268,249,107.38 from ¥4,053,927,701.84, indicating a reduction of about 5.3%[31]. - The company's inventory decreased to ¥302,975,017.15 from ¥371,066,828.31, showing a decline of about 18.4%[29]. - The company's long-term equity investments increased to ¥22,912,321.63 from ¥17,912,321.63, marking a growth of approximately 27.9%[30]. - The company's total equity decreased to ¥1,225,544,922.55 from ¥1,441,935,016.87, reflecting a decline of approximately 15%[32]. Shareholder Information - The total number of shareholders at the end of the reporting period was 49,053[11]. - The largest shareholder, Aoyang Group Co., Ltd., held 30.31% of the shares, amounting to 235,349,599 shares[11]. Cash Flow - Cash and cash equivalents increased by 46.43% compared to the beginning of the period, mainly due to an increase in bank acceptance bills issued[15]. - The cash flow from investment activities showed a net outflow of ¥200,524,727.94, compared to a larger outflow of ¥682,356,508.11 in the previous year[54]. - Cash flow from financing activities resulted in a net inflow of ¥135,102,131.89, down from ¥526,165,918.47 in the same period last year[54]. - The total cash and cash equivalents at the end of the period was ¥341,737,757.84, compared to ¥308,081,137.06 at the end of the previous year[54]. - The company received cash related to other operating activities amounting to ¥598,874,361.91, an increase from ¥494,162,905.95 in the previous year[53]. Investment Activities - Investment activities cash inflow increased by 1210.5% year-on-year, mainly due to increased cash recovery from wealth management products and demolition compensation[16]. - The total amount of funds raised through a private placement was approximately RMB 384 million, with net proceeds of about RMB 369 million[20]. - As of September 30, 2020, the company had utilized approximately RMB 252.51 million of the raised funds[20]. - The balance of the special account for raised funds at the end of the period was RMB 18.85 million[20]. Operational Insights - The company plans to enhance market expansion and operational efficiency to mitigate risks associated with the viscose staple fiber industry[17]. - The gross margin for viscose staple fiber products was negative, indicating potential impairment risks if market prices do not improve in Q4[17]. - The company reported non-operating income of ¥151,975,461.58 for the year-to-date[9]. Miscellaneous - The third quarter report of Jiangsu Aoyang Health Industry Co., Ltd. was not audited[58]. - The company implemented new revenue and lease standards starting from 2020, but did not apply retrospective adjustments to prior comparative data[58]. - The legal representative of the company is Shen Xueru[58]. - The financial report adjustments for the year 2020 were not applicable[58]. - The company has not disclosed any specific performance metrics or user data in the provided content[58]. - There is no mention of future outlook or performance guidance in the content[58]. - No new products or technologies were discussed in the provided content[58]. - There are no details regarding market expansion or mergers and acquisitions in the content[58]. - The company did not provide any new strategies in the content[58]. - The content does not include any financial figures or percentages related to performance[58].